DL‑3‑n‑butylphthalide reduces microglial activation in lipopolysaccharide‑induced Parkinson's disease model mice

Chen,Yuhua; Jiang,Mujun; Li,Li; Ye,Ming; Yu,Meiling; Zhang,Lina; Ge,Bobo; Xu,Wenfang; Wei,Daoxiang

doi:10.3892/mmr.2017.8332

March-2018 Volume 17 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2018 Volume 17 Issue 3

Full Size Image

Article

DL‑3‑n‑butylphthalide reduces microglial activation in lipopolysaccharide‑induced Parkinson's disease model mice

Authors:
- Yuhua Chen
- Mujun Jiang
- Li Li
- Ming Ye
- Meiling Yu
- Lina Zhang
- Bobo Ge
- Wenfang Xu
- Daoxiang Wei
View Affiliations / Copyright

Affiliations: Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China, Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China
Pages: 3884-3890
|
Published online on: December 20, 2017

https://doi.org/10.3892/mmr.2017.8332
Expand metrics +

Abstract

As microglial activation is a key factor in the pathogenesis of Parkinson's disease (PD), drugs that target this process may help to prevent or delay the development of PD. The present study investigated the effects of dl‑3‑n‑butylphthalide (NBP) on microglia in a lipopolysaccharide (LPS)-induced PD mouse model. The mice were randomly divided into a blank control group, LPS control group and NBP + LPS treatment group. Mice in the treatment group were given an intragastric infusion of 120 mg/kg NBP daily for 30 days during the establishment of the PD mouse model. At 4 and 28 weeks post‑treatment, the motor behaviours of the mice in each group were observed using the rotarod test and the open field test. In addition, immunohistochemical staining was performed to determine the levels of activated microglia, tumour necrosis factor‑α and α‑synuclein, and the number of tyrosine hydroxylase (TH)‑positive cells in the substantia nigra. NBP significantly improved dyskinesia, reduced microglial activation, decreased nuclear α‑synuclein deposition and increased the survival of TH‑positive cells in the substantia nigra of LPS‑induced PD model mice. These findings suggested that NBP may exert its therapeutic effect by reducing microglial activation in a mouse model of PD.

View Figures

View References

1	Venda LL, Cragg SJ, Buchman VL and Wade-Martins R: α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci. 33:559–568. 2010. View Article : Google Scholar : PubMed/NCBI
2	Calabresi P and Di Filippo M: Multitarget disease-modifying therapy in Parkinson's disease? Lancet Neurol. 14:975–976. 2015. View Article : Google Scholar : PubMed/NCBI
3	Peterson DS, Pickett KA and Earhart GM: Effects of levodopa on vividness of motor imagery in parkinson disease. J Parkinsons Dis. 2:127–133. 2012.PubMed/NCBI
4	Gagne JJ and Power MC: Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis. Neurology. 74:995–1002. 2010. View Article : Google Scholar : PubMed/NCBI
5	Lema Tomé CM, Tyson T, Rey NL, Grathwohl S, Britschgi M and Brundin P: Inflammation and α-synuclein's prion-like behavior in Parkinson's disease-is there a link? Mol Neurobiol. 47:561–574. 2013. View Article : Google Scholar : PubMed/NCBI
6	Grozdanov V, Bliederhaeuser C, Ruf WP, Roth V, Fundel-Clemens K, Zondler L, Brenner D, Martin-Villalba A, Hengerer B, Kassubek J, et al: Inflammatory dysregulation of blood monocytes in Parkinson's disease patients. Acta Neuropathol. 128:651–663. 2014. View Article : Google Scholar : PubMed/NCBI
7	Fernández-Calle R, Vicente-Rodríguez M, Gramage E, Pita J, Pérez-García C1, Ferrer-Alcón M, Uribarri M, Ramos MP and Herradón G: Pleiotrophin egulates microglia-mediated neuroinflammation. J Neuroinflammation. 14:462017. View Article : Google Scholar : PubMed/NCBI
8	Alhadidi Q and Shah ZA: Cofilin mediates LPS-induced microglial cell activation and associated neurotoxicity through activation of NF-κB and JAK-STAT pathway. Mol Neurobiol. Feb 13–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
9	Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ and Crews FT: Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 55:453–462. 2007. View Article : Google Scholar : PubMed/NCBI
10	Cui LY, Zhu YC, Gao S, Wang JM, Peng B, Ni J, Zhou LX, He J and Ma XQ: Ninety-day administration of dl-3-n-butylphthalide for acute ischemic stroke: A randomized, double-blind trial. Chin Med J (Engl). 126:3405–3410. 2013.PubMed/NCBI
11	Gan-Or Z, Dion PA and Rouleau GA: Genetic perspective on the role of theautophagy-lysosome pathway in Parkinson disease. Autophagy. 11:1443–1457. 2015. View Article : Google Scholar : PubMed/NCBI
12	Hoban DB, Connaughton E, Connaughton C, Hogan G, Thornton C, Mulcahy P, Moloney TC and Dowd E: Further characterisation of the LPS model of Parkinson's disease: A conparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis andnigrostriatal neurodegeneration in the rat. Brain Behav Immun. 27:91–100. 2013. View Article : Google Scholar : PubMed/NCBI
13	Kelly LP, Carvey PM, Keshavarzian A, Shannon KM, Shaikh M, Bakay RA and Kordower JH: Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord. 29:999–1009. 2014. View Article : Google Scholar : PubMed/NCBI
14	Bronstein DM, Perez-Otano I, Sun V, Mullis Sawin SB, Chan J, Wu GC, Hudson PM, Kong LY, Hong JS and McMillian MK: Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res. 704:112–116. 1995. View Article : Google Scholar : PubMed/NCBI
15	Xing B, Xin T, Hunter RL and Bing G: Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J Neuroinflammation. 5:42008. View Article : Google Scholar : PubMed/NCBI
16	Feng X, Peng Y, Liu M and Cui L: DL-3-n-butylphthalide extends survival by attenuating glial activation in a mouse model of amyotrophic lateral sclerosis. Neuropharmacology. 62:1004–1010. 2012. View Article : Google Scholar : PubMed/NCBI
17	Xu HL and Feng YP: Inhibitory effects of chiral 3-n-butylphthalide on inflammation following focal ischemic brain injury in rats. Acta Pharmacol Sin. 21:433–438. 2000.PubMed/NCBI
18	Hua K, Sheng X, Li TT, Wang LN, Zhang YH, Huang ZJ and Ji H: The edaravone and 3-n-butylphthalide ring-opening derivative 10b effectively attenuates cerebral ischemia injury in rats. Acta Pharmacol Sin. 36:917–927. 2015. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

DL‑3‑n‑butylphthalide reduces microglial activation in lipopolysaccharide‑induced Parkinson's disease model mice

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Related Articles